2020—2022年某三级甲等综合医院国家谈判药品落地实践研究  

Practical Research on the Use of National Negotiated Drugs in a Grade-A Tertiary General Hospital from 2020 to 2022

作　　者：孙家艳 顾云霞 陈春玲 徐文俊 朱华 谈定玉 SUN Jiayan;GU Yunxia;CHEN Chunling;XU Wenjun;ZHU Hua;TAN Dingyu(Northern Jiangsu People's Hospital·Northern Jiangsu People's Hospital Affiliated to Yangzhou University,Yangzhou,Jiangsu,China 225001)

机构地区：[1]江苏省苏北人民医院·扬州大学附属苏北人民医院,江苏扬州225001

出　　处：《中国药业》2025年第4期36-40,共5页China Pharmaceuticals

基　　金：江苏省药学会-正大天晴医院药学科研基金[Q202238];江苏省中药骨干人才高级研修项目[苏中医科教[2022]17号]。

摘　　要：目的 分析国家谈判药品(简称国谈药)在三级甲等综合医院的配备与使用情况。方法 收集2019-2021年国家医疗保障局(医保局)、江苏省医保局、扬州市医保局发布的国谈药“、双通道”药品、特药相关信息,以及查阅医院信息系统,分析2020-2022年相关药品在医院的使用数据。结果 2020—2022年国谈药整体品种配备比例分别为33.90%,33.94%,40.00%;使用金额占比分别为4.72%,7.00%,9.43%;其中中成药以调入品种为主,使用金额占比较小。“双通道”政策下国家谈判药品门诊使用金额及占比均大幅提升(由128.21万元升至3 111.59万元,3.91%升至49.39%)。调入/调出国谈药目录对药品使用金额的影响不完全相同。结论 国谈药的可及性不断提高,定点医疗机构对单独支付药品配备使用的主体责任仍需进一步强化。国谈药的新品遴选应同步考察临床需求,避免药品进入医保目录却无市场需求的情况。对于调出药品的衔接管理模式,尚需多方协同,提高医疗机构的积极性。Objective To analyze the allocation and use of national negotiated drugs in grade-A tertiary general hospitals.Methods The information related to national negotiated drugs,″dual-channel″drugs and special drugs released by the National Healthcare Security Administration,Jiangsu Healthcare Security Administration and Yangzhou Healthcare Security Administration from 2019 to 2021 was collected,the data of drug use in the hospital from 2020 to 2022 were analyzed based on the hospital information system.Results The overall variety allocation ratios of national negotiated drugs from 2020 to 2022 were 33.90%,33.94%,40.00%respectively,the proportions of consumption sum were 4.72%,7.00%,9.43%respectively;among them,the Chinese patent medicines were mainly transferred to the national negotiated drug catalogue,with small consumption sum.Under the″dual-channel″policy,the consumption sum and proportion of outpatient negotiated drugs significantly increased(from CNY 1.2831 million to CNY 31.1159 million,from 3.91%increased to 49.39%).Transfer-in/transfer-out of the national negotiated drug catalogue had a certain effect on the drug consumption sum.Conclusion The accessibility of national negotiated drugs is constantly improving,and the main responsibility of designated medical institutions for separate payment drugs still needs to be further strengthened.Clinical needs shoud be considered simultaneously during the selection of new drugs to negotiate to avoid there is no market demand after negotiated drugs entering the medical insurance catalogue.Multi-party collaboration is needed for the connection management mode of transfer-out drugs to improve the motivation of medical institutions.

关 键 词：国家谈判药品 三级甲等综合医院 “双通道”管理 药品可及性 

分 类 号：R95[医药卫生—药学]